血流储备分数指导的完全血运重建与仅罪犯血管血运重建在非ST段抬高型心肌梗死合并多支血管病变中的比较:SLIM随机临床试验
该前瞻性、研究者发起、多中心、国际随机临床试验在9家欧洲医院纳入478例非ST段抬高型心肌梗死合并多支血管病变且罪犯血管血运重建成功的患者,比较血流储备分数(FFR)指导的完全血运重建与仅罪犯血管血运重建。1年时主要复合终点在完全血运重建组为5.5%,仅罪犯血管组为13.6%(HR 0.38,95%CI 0.20-0.72,P=0.003),主要由再次血运重建减少驱动。
要点
- FFR指导的完全血运重建组1年主要复合终点发生率为5.5%,仅罪犯血管组为13.6%(HR 0.38,95%CI 0.20-0.72,P=0.003)。
- 任何血运重建发生率完全血运重建组为3.0%,仅罪犯血管组为11.5%(HR 0.24,95%CI 0.11-0.56,P<0.001)。
- 净不良临床事件发生率完全血运重建组为6.3%,仅罪犯血管组为15.3%(HR 0.39,95%CI 0.21-0.70,P=0.002)。
核心结论
- 在非ST段抬高型心肌梗死合并多支血管病变患者中,index procedure期间行FFR指导的完全血运重建显著降低1年全因死亡、非致死性心肌梗死、任何血运重建和卒中的复合终点,主要由再次血运重建减少驱动。
研究设计与样本
- 前瞻性、研究者发起、多中心、国际随机临床试验,在欧洲9家医院开展。
- 2018年6月至2024年7月纳入非ST段抬高型心肌梗死合并多支血管病变且罪犯病变血运重建成功的患者,最终随访于2025年7月21日完成,分析于2025年7月28日进行。
- 纳入标准包括至少1处非罪犯病变狭窄程度至少50%且适合血运重建。
- 共478例患者随机,平均(标准差)年龄65.9(10.6)岁,男性347例(72.9%);240例分配至FFR指导的完全血运重建组,238例分配至仅罪犯血管血运重建组,仅罪犯血管组有7例交叉。
主要发现
- 主要复合终点(1年全因死亡、非致死性心肌梗死、任何血运重建和卒中)在FFR指导的完全血运重建组发生13例(5.5%),仅罪犯血管组发生32例(13.6%)(HR 0.38,95%CI 0.20-0.72,P=0.003)。
- 任何血运重建发生率完全血运重建组为3.0%,仅罪犯血管组为11.5%(HR 0.24,95%CI 0.11-0.56,P<0.001)。
- 净不良临床事件发生率完全血运重建组为6.3%,仅罪犯血管组为15.3%(HR 0.39,95%CI 0.21-0.70,P=0.002)。
- 其余次要结局无显著差异。
关键数值与推荐
- 主要终点为1年全因死亡、非致死性心肌梗死、任何血运重建和卒中的复合终点。
- 关键次要结局包括主要终点的各组成部分、净不良临床事件、全因死亡或非致死性心肌梗死、心脏再住院和出血事件。
- 仅罪犯血管组允许在index procedure后6周内行分期血运重建。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The benefits of fractional flow reserve (FFR)-guided complete coronary revascularization in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remain unclear. OBJECTIVE: To compare FFR-guided complete revascularization of nonculprit lesions vs culprit-only revascularization in patients with NSTEMI and multivessel disease. DESIGN, SETTING, AND PARTICIPANTS: This prospective, investigator-initiated, multicenter, international randomized clinical trial was conducted at 9 hospitals in Europe. Patients with NSTEMI and multivessel disease who had successful revascularization of the culprit lesion were enrolled between June 2018 and July 2024, and final follow-up was completed on July 21, 2025. The analysis was conducted on July 28, 2025. Eligibility criteria included the presence of at least 1 stenosis of at least 50% in a nonculprit lesion amendable for revascularization. INTERVENTION: Patients were randomized to receive either FFR-guided complete or culprit-only revascularization during the index procedure. Staged revascularization within 6 weeks after the index procedure was allowed in the culprit-only group. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. Key secondary outcomes included individual components of the primary outcome, net adverse clinical events, all-cause death or nonfatal myocardial infarction, cardiac rehospitalization, and bleeding events. RESULTS: Among 478 randomized patients (mean [SD] age, 65.9 [10.6] years; 347 [72.9%] males), 240 were randomized to receive FFR-guided complete revascularization and 238 were randomized to receive culprit-only revascularization, with crossover occurring in 7 patients in the culprit-only group. The primary outcome occurred in 13 patients (5.5%) in the FFR-guided complete revascularization group vs 32 patients (13.6%) in the culprit-only group (hazard ratio [HR], 0.38 [95% CI, 0.20-0.72]; P = .003). Rates of any revascularization (3.0% vs 11.5%; HR, 0.24 [95% CI, 0.11-0.56]; P < .001) and net adverse clinical events (6.3% vs 15.3%; HR, 0.39 [95% CI, 0.21-0.70]; P = .002) were also significantly lower in the complete revascularization group, while there were no significant differences in the remaining secondary outcomes. CONCLUSION AND RELEVANCE: FFR-guided complete revascularization during the index procedure resulted in a significant reduction in the composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. This was mainly driven by reduced repeat revascularization. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03562572.
引用
- Pustjens TFS, Veenstra L, Camaro C, et al. Fractional Flow Reserve-Guided Complete vs Culprit-Only Revascularization in Non-ST-Elevation Myocardial Infarction and Multivessel Disease: The SLIM Randomized Clinical Trial. JAMA. 2025. PMID: 40886310. doi:10.1001/jama.2025.16189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。